ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Ironwood Pharmaceuticals 

301 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-7722 Fax: 617-494-0480


SEARCH JOBS

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.


 Key Statistics


Email:
Ownership: Public

Web Site: Ironwood Pharmaceuticals
Employees:
Symbol: IRWD
 



Industry
Pharmaceutical






 Company News
EXACT Sciences Corporation (EXAS) And Ironwood Pharmaceuticals (IRWD) Enter Co-Promotion Agreement For Cologuard 3/9/2015 9:57:27 AM
Ironwood Pharmaceuticals (IRWD) To Present At Barclays Global Healthcare Conference 3/5/2015 11:03:56 AM
Ironwood Pharmaceuticals (IRWD) Initiates Phase I Clinical Study Of sGC Stimulator IW-1973 3/5/2015 10:03:20 AM
Ironwood Pharmaceuticals (IRWD) To Present At Cowen and Company 35th Annual Health Care Conference 2/24/2015 12:08:59 PM
Ironwood Pharmaceuticals (IRWD) Provides Fourth Quarter 2014 Investor Update 2/13/2015 10:03:27 AM
Ironwood Pharmaceuticals (IRWD) Reports Positive Top-Line Data From Exploratory Phase IIa Trial Of IW-3718 In Refractory Gastroesophageal Reflux Disease 2/4/2015 10:59:16 AM
Ironwood Pharmaceuticals (IRWD) To Host Fourth Quarter 2014 Investor Update Call 1/30/2015 10:49:51 AM
Ironwood Pharmaceuticals (IRWD)To Present At J.P. Morgan Healthcare Conference 1/6/2015 11:29:57 AM
Ironwood Pharmaceuticals (IRWD) Initiates Phase 2a Clinical Study Of IW-9179 In Diabetic Gastroparesis 12/9/2014 11:18:52 AM
Ironwood Pharmaceuticals (IRWD) Earns $15 Million Milestone From Astellas Pharma Inc. (ALPMY) 11/20/2014 7:13:50 AM
12345678910...